FDA Accepts New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension

Posted on

Allergan announced that the U.S. FDA accepted their New Drug Application for Bimatoprost Sustained-Release (SR). The FDA is expected to take action on the New Drug Application by the end of the first half of 2020.

In two Phase 3 ARTEMIS studies, Bimatoprost SR reduced intraocular pressure (IOP) by 30% over a 12-week primary efficacy period. The studies included 1,122 participants with open-angle glaucoma or ocular hypertension and evaluated the efficacy and safety of Bimatoprost SR versus timolol. After three treatments with Bimatoprost SR, more than 80% of patients remained treatment-free and did not need additional treatment to maintain IOP control for at least 12 months. Bimatoprost SR was well tolerated in most patients.

According to Robert Weinreb, MD, Chairman & Distinguished Professor of Ophthalmology and Director of the Shiley Eye Institute, San Diego, Bimatoprost SR “has the potential to be the first sustained-release option that could significantly shift the paradigm for treating glaucoma.”

You can read more here.

Related Articles
IOP outcomes after laser trabeculoplasty in eyes with prior Kahook Dual Blade goniotomy limited
Jul 28, 2021
Hydrus microstent reduces IOP, medication burden
Jul 26, 2021
IOP, gel microstents complications leading cause of reoperation after MIGS
Jul 23, 2021